BioMed Research International / 2017 / Article / Tab 4 / Research Article
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study Table 4 Multivariate analyses of prognostic factors for progression-free survival in first-line sorafenib-treated patients (
).
Parameter Univariate analysis of PFS Multivariate analysis of PFS Hazard ratio valueConfidence interval Hazard ratio valueConfidence interval Gender, female 0.56 0.066 0.30–1.04 Age ≥65 years 1.04 0.859 0.66–1.66 KPS <80% 1.87 0.062 0.97–3.61 LDH >1.5x ULN 0.70 0.625 0.17–2.90 Hemoglobin <LLN 1.78 0.019 1.10–2.87 0.41 0.220 0.10–1.70 cCa >10 mg/dL 0.83 0.684 0.33–2.06 Time from diagnosis to treatment <1 year 2.88 0.000 1.72–4.81 1.90 0.242 0.65–5.59 Leukocytosis 2.35 0.032 1.08–5.13 2.41 0.274 0.50–11.61 Thrombocytosis 4.06 0.001 1.78–9.30 0.83 0.875 0.09–8.02 Hypoalbuminemia 1.93 0.089 0.91–4.10 Prior nephrectomy 1.98 0.499 0.27–14.33 Prior metastasectomy 0.89 0.683 0.52–1.53 Brain metastasis 1.04 0.867 0.63–1.73 Bone metastasis 1.65 0.066 0.97–2.81 Liver metastasis 2.16 0.058 0.98–4.80 Lung metastasis 0.72 0.187 0.44–1.17 Lymph node metastasis 1.82 0.040 1.03–3.23 1.98 0.365 0.45–8.72 Pancreas 1.16 0.708 0.53–2.56 Contralateral kidney 0.23 0.149 0.03–1.69 Metastatic sites 1 1.00 1.00 2-3 1.28 0.320 0.78–2.10 0.80 0.783 0.17–3.80 4 3.96 0.012 1.35–11.56 28.57 0.019 1.74–468.69 T stage T1-2 1.00 1.00 T3-4 1.97 0.008 1.19–3.26 4.34 0.025 1.20–15.71 N1 2.66 0.001 1.51–4.68 0.75 0.837 0.05–11.95 M1 2.08 0.044 1.02–4.22 0.75 0.674 0.20–2.86 Fuhrman grade 1-2 1.00 3-4 0.98 0.955 0.57–1.71 Primary tumor size <4 cm 1.00 4–7 cm 0.87 0.737 0.37–2.00 0.37 0.288 0.06–2.30 >7 cm 0.85 0.690 0.39–1.86 0.31 0.186 0.05–1.76 Collecting system invasion 2.11 0.026 1.09–4.07 0.07 0.012 0.01–0.55 Capsule invasion 1.05 0.869 0.59–1.88 Lymphovascular invasion 2.41 0.004 1.33–4.37 13.35 0.009 1.91–93.37 Tumor necrosis 2.01 0.022 1.10–3.65 6.69 0.002 2.06–21.73
KPS, Karnofsky performance status; LDH, lactate dehydrogenase; ULN, upper limit normal; LLN, lower limit normal; cCa, corrected calcium.